Literature DB >> 10081484

A long-term follow-up study on risk factors for hepatocellular carcinoma among Japanese patients with liver cirrhosis.

K Tanaka1, H Sakai, M Hashizume, T Hirohata.   

Abstract

To identify virological parameters (serostatus of hepatitis B surface antigen [HBsAg] and antibodies to hepatitis C virus [anti-HCV], HCV genotypes and HCV-RNA titer) and other clinico-biological and lifestyle variables that may influence or predict the development of hepatocellular carcinoma (HCC) in cirrhosis, we followed 100 cirrhotic patients without HCC, who visited Kyushu University Hospital between 1985 and 1987, until the end of 1995 (follow-up rate: 98%; average follow-up period: 5.3 years). After elimination of 4 patients who developed HCC or were censored within the initial 6 months, 37 (39%) out of 96 patients developed HCC during follow-up. As compared with HBsAg(+) patients, anti-HCV(+) HBsAg(-) patients demonstrated significantly elevated HCC risk (adjusted hazard ratio [HR] = 5.85, 95% confidence interval [CI] 1.65-20.67). Genotype 1 HCV infection was not associated with increased risk compared with genotype 2 (HR = 0.64, 95% CI 0.21-1.99). For genotype 1 HCV infection, patients with HCV-RNA levels < 1 Meq/ml tended to present lower risk than patients with > or = 1 Meq/ml (P = 0.03). Male sex, advanced Child's class, lower serum albumin, and higher serum aminotransferase and alpha-fetoprotein were also found to be strong predictors. Overall, drinking and smoking habits were not associated with significantly elevated risk. Among virological parameters, anti-HCV positivity and, possibly high HCV-RNA titer, were predictive of HCC occurrence in cirrhosis in our clinical setting.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10081484      PMCID: PMC5921737          DOI: 10.1111/j.1349-7006.1998.tb00520.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  27 in total

1.  Hepatitis C virus 1b, cirrhosis, and hepatocellular carcinoma.

Authors:  C Brechot
Journal:  Hepatology       Date:  1997-03       Impact factor: 17.425

2.  Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis.

Authors:  L Benvegnù; P Pontisso; D Cavalletto; F Noventa; L Chemello; A Alberti
Journal:  Hepatology       Date:  1997-01       Impact factor: 17.425

3.  Risk factors in development of hepatocellular carcinoma in cirrhosis: prospective study of 613 patients.

Authors:  S N Zaman; W M Melia; R D Johnson; B C Portmann; P J Johnson; R Williams
Journal:  Lancet       Date:  1985-06-15       Impact factor: 79.321

4.  Risk factors for hepatocellular carcinoma among patients with chronic liver disease.

Authors:  H Tsukuma; T Hiyama; S Tanaka; M Nakao; T Yabuuchi; T Kitamura; K Nakanishi; I Fujimoto; A Inoue; H Yamazaki
Journal:  N Engl J Med       Date:  1993-06-24       Impact factor: 91.245

5.  A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis.

Authors:  K Ikeda; S Saitoh; I Koida; Y Arase; A Tsubota; K Chayama; H Kumada; M Kawanishi
Journal:  Hepatology       Date:  1993-07       Impact factor: 17.425

6.  Hepatocellular carcinoma in Italian patients with cirrhosis.

Authors:  M Colombo; R de Franchis; E Del Ninno; A Sangiovanni; C De Fazio; M Tommasini; M F Donato; A Piva; V Di Carlo; N Dioguardi
Journal:  N Engl J Med       Date:  1991-09-05       Impact factor: 91.245

7.  Hepatitis C and hepatitis B in the etiology of hepatocellular carcinoma in the Japanese population.

Authors:  K Tanaka; T Hirohata; S Koga; K Sugimachi; T Kanematsu; F Ohryohji; H Nawata; H Ishibashi; Y Maeda; H Kiyokawa
Journal:  Cancer Res       Date:  1991-06-01       Impact factor: 12.701

8.  Relationship of hepatitis C virus genotypes and viremia levels with development of hepatocellular carcinoma among Japanese.

Authors:  K Tanaka; T Hirohata
Journal:  Fukuoka Igaku Zasshi       Date:  1998-08

9.  Screening for hepatocellular carcinoma in patients with Child's A cirrhosis: an 8-year prospective study by ultrasound and alphafetoprotein.

Authors:  M Cottone; M Turri; M Caltagirone; P Parisi; A Orlando; G Fiorentino; R Virdone; G Fusco; R Grasso; R G Simonetti
Journal:  J Hepatol       Date:  1994-12       Impact factor: 25.083

10.  Past exposure to hepatitis B virus as a risk factor for hepatocellular carcinoma in patients with chronic liver disease.

Authors:  S Okada; T Sato; T Okusaka; H Ishii; M Ikeda; H Nakasuka; H Kosakamoto; M Yoshimori; K Wakabayashi
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more
  5 in total

1.  The prevalence of hepatitis C virus infection in Texas: implications for future health care.

Authors:  Kanthi Yalamanchili; Sherif Saadeh; Rita Lepe; Gary L Davis
Journal:  Proc (Bayl Univ Med Cent)       Date:  2005-01

Review 2.  Epidemiology of hepatocellular carcinoma in India.

Authors:  Subrat K Acharya
Journal:  J Clin Exp Hepatol       Date:  2014-06-20

3.  Assessment of KL-6 as a tumor marker in patients with hepatocellular carcinoma.

Authors:  Amal Gad; Eiji Tanaka; Akihiro Matsumoto; Moushira Abd-el Wahab; Abd el-Hamid Serwah; Fawzy Attia; Khalil Ali; Howayda Hassouba; Abd el-Raoof el-Deeb; Tetsuya Ichijyo; Takeji Umemura; Hidetomo Muto; Kaname Yoshizawa; Kendo Kiyosawa
Journal:  World J Gastroenterol       Date:  2005-11-14       Impact factor: 5.742

Review 4.  Psychosocial stress and liver disease status.

Authors:  Cristin Constantin Vere; Costin Teodor Streba; Letitia Maria Streba; Alin Gabriel Ionescu; Felix Sima
Journal:  World J Gastroenterol       Date:  2009-06-28       Impact factor: 5.742

Review 5.  Recent Advances in Anticancer Activity of Novel Plant Extracts and Compounds from Curcuma longa in Hepatocellular Carcinoma.

Authors:  Nighat Gull; Fareeha Arshad; Gowhar A Naikoo; Israr Ul Hassan; Mona Zamani Pedram; Arif Ahmad; Alaa A A Aljabali; Vijay Mishra; Saurabh Satija; Nitin Charbe; Poonam Negi; Rohit Goyal; Ángel Serrano-Aroca; Mazhar S Al Zoubi; Mohamed El-Tanani; Murtaza M Tambuwala
Journal:  J Gastrointest Cancer       Date:  2022-03-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.